公开(公告)号：US20240173294A1

公开(公告)日：2024-05-30

申请号：US18434065

申请日：2024-02-06

申请人： Société des Produits Nestlé S.A.

发明人： Md Ehtesham REZA ,  Vesselin Danailov MILADINOV ,  Richard Mark WARRINGTON

IPC分类号： A61K31/4045 ,  A61K9/00 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/46

CPC分类号： A61K31/4045 ,  A61K9/0056 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/46

摘要： The present invention relates to a composition comprising melatonin encapsulated within a calcium alginate hydrogel. It further provides an orally administrable dosage form comprising such a composition held within a gel, wherein the gel is formed using starch as a gelling agent. Processes to produce these compositions, as well as their use in therapy, are also disclosed.

公开(公告)号：US20240173263A1

公开(公告)日：2024-05-30

申请号：US17793540

申请日：2021-12-28

申请人： SIRIO PHARMA CO., LTD.

发明人： Xufa Li ,  Jiewei Chen

IPC分类号： A61K9/48 ,  A61K47/10 ,  A61K47/26 ,  A61K47/36

CPC分类号： A61K9/4816 ,  A61K47/10 ,  A61K47/26 ,  A61K47/36

摘要： The invention relates to a soft capsule shell and a soft capsule. The present invention provides soft capsule shells prepared from a film-forming composition including 2 wt % to 5 wt % of a first gelling agent, 10 wt % to 35 wt % of a plasticizer, 18 wt % to 35 wt % of gelatinizable starch, 4 wt % to 17 wt % of granular starch, and 35 wt % to 55 wt % of water, wherein the first gelling agent is a gellan gum having a weight-average molecular weight of 5.0×105 to 8.0×106 g/mol and/or a coefficient of molecular weight distribution of 1.0 to 6.0. The film-forming composition provided by the invention has good film-forming mechanical strength, toughness and viscosity, is good in seaming when being compressed into soft capsules, and can be disintegrated in medium water and simulated gastric juice.

公开(公告)号：US20240166636A1

公开(公告)日：2024-05-23

申请号：US18471734

申请日：2023-09-21

申请人： Epizyme, Inc.

发明人： Marinus Jacobus VERWIJS ,  David Jon AM ENDE ,  Stephen Richard ANDERSON ,  Andrew Paul George BEEVERS ,  Mark Kenneth BREAULT ,  Stephen Richard TUDHOPE ,  Jamie Ross WOLSTENHULME

IPC分类号： C07D405/12 ,  A61K9/14 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38

CPC分类号： C07D405/12 ,  A61K9/14 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  C07B2200/13

摘要： Provided herein are methods for making a crystalline form of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide and related products, compositions and treatment methods.

公开(公告)号：US20240165190A1

公开(公告)日：2024-05-23

申请号：US18281545

申请日：2022-03-11

申请人： Sadanand Prabhakar SARDESHMUKH

发明人： Sadanand Prabhakar SARDESHMUKH ,  Vineeta Vasant DESHMUKH

IPC分类号： A61K36/8965 ,  A61K36/35 ,  A61K36/59 ,  A61K36/61 ,  A61K36/67 ,  A61K47/36 ,  A61P35/04

CPC分类号： A61K36/8965 ,  A61K36/35 ,  A61K36/59 ,  A61K36/61 ,  A61K36/67 ,  A61K47/36 ,  A61P35/04

摘要： The present disclosure relates to a herbo-mineral metallic pharmaceutical kit for delaying/controlling recurrence and/or metastasis of cancer in Triple Negative Breast Cancer (TNBC) patients. The herbo-mineral metallic pharmaceutical kit comprises a first container containing Suvarna Bhasmadi Vati (SBV), a second container containing Mouktikyukta Kamdudha Vati (MKV), a third container containing Shatavari Vati (SV), a fourth container containing Arogyavardhini Vati (AVV), a fifth container containing Triphala Guggul Vati (TGV) and a sixth container containing jatamansi Oil (JMO). The herbo mineral metallic pharmaceutical kit assists in improving immunomodulatory response and reducing oxidative stress in TNBC patients.

公开(公告)号：US20240165141A1

公开(公告)日：2024-05-23

申请号：US18291880

申请日：2022-07-25

申请人： Daré Bioscience, Inc.

发明人： David Friend ,  Jennifer Kiang ,  Nicolas J. Pacelli ,  Mark Walters

IPC分类号： A61K31/7056 ,  A61K9/00 ,  A61K9/06 ,  A61K47/10 ,  A61K47/36 ,  A61P15/02

CPC分类号： A61K31/7056 ,  A61K9/0034 ,  A61K9/06 ,  A61K47/10 ,  A61K47/36 ,  A61P15/02

摘要： A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity of at least 1.5 million mPa·s.

公开(公告)号：US20240165024A1

公开(公告)日：2024-05-23

申请号：US18422105

申请日：2024-01-25

申请人： LIQMEDS WORLDWIDE LIMITED

发明人： Sandip MEHTA ,  Manish UMRETHIA ,  Henil PATEL ,  Jayanta Kumar MANDAL

IPC分类号： A61K9/00 ,  A61K9/10 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36

CPC分类号： A61K9/0095 ,  A61K9/0053 ,  A61K9/10 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36

摘要： Disclosed herein is a pharmaceutical oral suspension, comprising: mycophenolate mofetil in an amount of about 200 mg/mL; one or more cosolvents comprising ethanol, a polyethylene glycol, a sorbitol, glycerin, propylene glycol, benzyl alcohol, or a combination thereof in an amount of from about 5% w/w to about 30% w/w; one or more pharmaceutically acceptable excipients selected from a suspending agent, a preservative, a sweetener, an antifoaming agent, a wetting agent, a buffering agent, and a flavoring agent; and a vehicle comprising water. The pharmaceutical oral suspension has improved stability, palatability with high dose of active ingredient.

公开(公告)号：US11986528B2

公开(公告)日：2024-05-21

申请号：US17443485

申请日：2021-07-27

申请人： GATTEFOSSE SAS

发明人： Amandine Forest ,  Jean-David Rodier

IPC分类号： A61K47/36 ,  A61K9/16 ,  A61K47/10

CPC分类号： A61K47/36 ,  A61K9/1682 ,  A61K47/10

摘要： The invention concerns the use, as a pharmaceutical or cosmetic excipient, of a composition which is solid at ambient temperature and in the form of individualized particles, said composition comprising:



lauroyl macrogolglyceride,
polyethylene glycol.

公开(公告)号：US20240157101A1

公开(公告)日：2024-05-16

申请号：US18550371

申请日：2022-03-18

申请人： THE JOHNS HOPKINS UNIVERSITY

发明人： David H. Gracias ,  Florin M. Selaru ,  Arijit Ghosh

IPC分类号： A61M31/00 ,  A61K9/00 ,  A61K47/36

CPC分类号： A61M31/002 ,  A61K9/0031 ,  A61K9/0053 ,  A61K47/36

摘要： The present disclosure provides microscale devices, systems, and methods thereof for the delivery of therapeutic and prophylactic active agents (e.g., macromolecules).

公开(公告)号：US20240156839A1

公开(公告)日：2024-05-16

申请号：US18548741

申请日：2022-03-04

申请人： TAIWAN LIPOSOME COMPANY, LTD. ,  TLC BIOPHARMACEUTICALS, INC.

发明人： Sheue-Fang SHIH ,  Hsin-Yi CHIU

IPC分类号： A61K31/573 ,  A61K9/00 ,  A61K9/06 ,  A61K9/127 ,  A61K39/00 ,  A61K47/36 ,  C07K16/22

CPC分类号： A61K31/573 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/06 ,  A61K9/1272 ,  A61K47/36 ,  C07K16/22 ,  A61K2039/54 ,  C07K2317/24

摘要： Provided is a pharmaceutical composition for delivery of an active agent to an eye. The pharmaceutical composition may comprise a lipid mixture; an active agent and a biocompatible hydrogel. The pharmaceutical composition achieves a prolonged therapeutic effect as well as reduced side effects. Also provided is a method of delivering an active agent in the pharmaceutical composition to an eye of a subject in need thereof.

公开(公告)号：US20240156793A1

公开(公告)日：2024-05-16

申请号：US18057941

申请日：2022-11-22

申请人： Lumos Pharma, Inc.

发明人： Alpa B. PARIKH ,  John C. McKEW

IPC分类号： A61K31/438 ,  A61K9/20 ,  A61K9/28 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P5/06

CPC分类号： A61K31/438 ,  A61K9/2077 ,  A61K9/2846 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P5/06

摘要： The present disclosure relates to pharmaceutical solid forms and pharmaceutical compositions comprising ibutamoren or a pharmaceutically acceptable salt thereof, and methods for administering to a pediatric subject for treating growth hormone deficiency.